The Future of Breast Cancer Screening (cont.)
Researchers at Dartmouth College in New Hampshire are simultaneously studying four of these screening techniques: NIR, MIS, EIS, and MRE. If one or more of these methods are found to be promising, scientists might look into integrating the technologies into a single tool.
"We're excited about the possibilities, but there's a lot to be worked out," says Keith Paulsen, PhD, principal investigator of Dartmouth's Breast Imaging Project.
Clinical trials began April 2003, and may wrap up next summer. An interim analysis with official statistics on the success of each technique is due in the next couple of weeks; meantime, Paulsen is optimistic. "The projects are going well," he says.
Next: Detecting cancer before it starts.
Looking Into a Biological Crystal Ball
Several studies are currently looking into the possibility of diagnosing breast cancer at the cellular level. There is hope that someday researchers will be able to identify a turning point when biological substances become cancerous, thus leading to development of methods for detecting warning signals.
The National Cancer Institute alone has funded research into at least a half-dozen tests that involve examining typical and irregular proteins, molecules, genes, and other biological matter. One such large clinical trial in progress is a blood test. By analyzing concealed patterns of protein in blood, investigators propose being able to distinguish malignant tissues from benign ones.
Although this blood test is currently being tested only for ovarian cancer, researchers are hopeful the technology, once proven, could be adapted to other cancers. If everything goes well, investigators plan to compare the outcome of the trial with other blood test research around the country of other cancers.
One such study to detect breast cancer by looking at blood cells has already ended. The results? The blood test was 95% successful in spotting malignancies. The complete report is currently being reviewed for publication in a medical journal.
"Everything looks extremely exciting...but we want to move cautiously," says Lance Liotta, MD, PhD, a principal investigator of the Clinical Proteomics Program, and chief of the laboratory of pathology at the National Cancer Institute.
When could such a blood test become available? Liotta says that depends on three factors:
If all variables fall into place, however, he says the test could be on the market within the next 5 years -- unless competing private companies come up with the technology first.
How Better Screening Helps High-Risk Women
The technology to screen for genetic mutations is already available, but it is recommended only for women who have reason to believe they are at high risk for developing breast cancer, such as a strong family history.
In the early 1990s, it was found that women with certain mutated genes -- BRCA1 and BRCA2 -- tend to have a 50% to 85% risk of developing breast cancer.
Since then, the issue of genetic testing has been controversial. Some people say the presence of the mutated gene does not necessarily mean a woman will develop breast cancer, so a positive result could cause unwarranted concern. Plus, these genes account for relatively few cases of breast cancer. Also, there is fear that insurance companies and employers could discriminate against women who have the mutation.
Women who do decide to go through with genetic testing are advised to first undergo genetic counseling to help them deal with the information, and decide what to do about it.
Better technology for early detection could help women at high risk tremendously, says Judy Garber, MD, director of cancer risk and prevention at the Dana-Farber Cancer Institute.
"Instead of deciding at 30 to have your breasts removed because you might get breast cancer sometime in the next 50 years, maybe you could wait until you're 60, after you've had your children and you've gone through your life."
Medically updated September 26, 2003.
SOURCES: American Cancer Society. Robert A. Smith, PhD, American Cancer Society director of cancer screening. Keith Paulsen, PhD, principal investigator of Dartmouth's Breast Imaging Project. National Cancer Institute. Lance Liotta, MD, PhD, a principal investigator of the Clinical Proteomics Program, and chief of the laboratory of pathology at the National Cancer Institute. Judy Garber, MD, director of cancer risk and prevention at the Dana-Farber Cancer Institute.
©1996-2005 WebMD Inc. All rights reserved.
Last Editorial Review: 1/31/2005 4:45:51 AM